Metastatic Colorectal Cancer
Conditions
Brief summary
This study will focus on participants in the United Kingdom (UK) to collect local data on the effectiveness and safety of bevacizumab (Avastin) in the treatment of metastatic colorectal cancer in normal clinical use.
Interventions
OTHERNo intervention
No intervention administered in this study
Sponsors
Hoffmann-La Roche
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have been diagnosed with metastatic colorectal cancer (mCRC) * Have a Performance Status (PS) of 0-2, according to the Eastern Cooperative Oncology Group (ECOG) criteria at initiation of bevacizumab treatment * Be chemotherapy-naive at diagnosis of mCRC or have relapsed more than 12 months after receiving adjuvant chemotherapy for early stage colorectal cancer * Have received standard fluoropyrimidine-based chemotherapy for first-line treatment of mCRC with or without bevacizumab * Have sufficient medical records available for assessment of eligibility at the Christie Hospital National Health Service (NHS) Trust, Manchester, United Kingdom * For Cohort 1 (post CDF funding availability): patients between 2010-2013 who received bevacizumab with first-line chemotherapy * For Cohort 2 (pre Cancer Drugs Fund \[CDF\] funding availability): patients propensity matched to cohort 1 between 2005-2008 who did not receive bevacizumab with first-line chemotherapy
Exclusion criteria
* Subjects with metastatic colorectal cancer, who have received bevacizumab via a clinical trial * Subjects with metastatic colorectal cancer, whose medical records are not complete enough to confirm eligibility for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | From date of metastatic colorectal cancer diagnosis to date of death up to 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Response Rate (RR) | From date of metastatic colorectal cancer diagnosis to end of study up to 3 years |
| Progression Free Survival (PFS) | From date of metastatic colorectal cancer diagnosis to end of study up to 3 years |
| Percentage of Participants with Adverse Events of Special Interest | From date of metastatic colorectal cancer diagnosis to end of study up to 3 years |
Outcome results
None listed